195 related articles for article (PubMed ID: 11279803)
41. BIS-1: a novel bispecific monoclonal antibody for CEA-expressing carcinoma radioimmunoscintigraphy and radioimmunotherapy.
Parisi A; Bartolazzi A; Bonino C; Camagna M; DeMonte LB; Lombardi A; Natali PG; Paganelli G; Tarditi L; Vassarotto C
Year Immunol; 1993; 7():96-105. PubMed ID: 8372516
[No Abstract] [Full Text] [Related]
42. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
43. [Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer].
Oliva JP; Pimentel G; Borrón M; Peralta R; Ortiz R; Oliver B; Díaz N; Sánchez I; Vázquez AM; Baum RP
Rev Esp Med Nucl; 2001 Jun; 20(4):282-8. PubMed ID: 11940415
[TBL] [Abstract][Full Text] [Related]
44. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
[TBL] [Abstract][Full Text] [Related]
45. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
46. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II.
Ramos-Suzarte M; Pintado AP; Mesa NR; Oliva JP; Iznaga-Escobar N; Aroche LT; Pimentel G; González J; Cordero M; Rodríguezi OT; Crombet RT; Pérez RR
Cancer Biol Ther; 2007 Jan; 6(1):22-9. PubMed ID: 17224642
[TBL] [Abstract][Full Text] [Related]
48. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
Pai-Scherf LH; Carrasquillo JA; Paik C; Gansow O; Whatley M; Pearson D; Webber K; Hamilton M; Allegra C; Brechbiel M; Willingham MC; Pastan I
Clin Cancer Res; 2000 May; 6(5):1720-30. PubMed ID: 10815890
[TBL] [Abstract][Full Text] [Related]
49. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma.
Chen S; Li B; Xie H; Xu L; Niu G; Fan K; Fan Q
Cancer Biother Radiopharm; 2004 Oct; 19(5):589-600. PubMed ID: 15650451
[TBL] [Abstract][Full Text] [Related]
50. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
51. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B; Witteveen PO; Ruijter R; Giaccone G; Dontabhaktuni A; Fox F; Katz T; Youssoufian H; Zhu J; Rowinsky EK; Voest EE
Clin Cancer Res; 2010 Mar; 16(6):1915-23. PubMed ID: 20197484
[TBL] [Abstract][Full Text] [Related]
52. In vivo study of a technetium labelled anti-EGFr MoAB.
Scopinaro F; De Vincentis G; Banci M; Schillaci O; Di Loreto M; Danieli R; Ierardi M; De Paola AM; Gianni W; Massa R
Anticancer Res; 1997; 17(3B):1761-5. PubMed ID: 9179231
[TBL] [Abstract][Full Text] [Related]
53. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
54. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
Borchmann P; Schnell R; Fuss I; Manzke O; Davis T; Lewis LD; Behnke D; Wickenhauser C; Schiller P; Diehl V; Engert A
Blood; 2002 Nov; 100(9):3101-7. PubMed ID: 12384405
[TBL] [Abstract][Full Text] [Related]
55. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
56. Immunoscintigraphy with a technetium-99m labelled anti-epithelial growth factor receptor antibody in patients with non-small cell lung cancer.
Schillaci O; Danieli R; Picardi V; Bagni O; Di Loreto M; Scopinaro F
Anticancer Res; 2001; 21(5):3571-4. PubMed ID: 11848525
[TBL] [Abstract][Full Text] [Related]
57. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
Divgi CR; Welt S; Kris M; Real FX; Yeh SD; Gralla R; Merchant B; Schweighart S; Unger M; Larson SM
J Natl Cancer Inst; 1991 Jan; 83(2):97-104. PubMed ID: 1988695
[TBL] [Abstract][Full Text] [Related]
58. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
